Plasma p-Tau217 Flags Alzheimer’s Pathology in Other Disorders
The marker detected plaques and tangles with 90 percent accuracy in almost 200 autopsy-confirmed frontotemporal dementia cases.
6654 RESULTS
Sort By:
The marker detected plaques and tangles with 90 percent accuracy in almost 200 autopsy-confirmed frontotemporal dementia cases.
Plasma Aβ42/40 ratios drop in people soon after COVID-19 infection even for mild cases. Does this mean they are at higher risk for dementia?
Amyloid and tau accumulation patterns differ in black, white, and Hispanic people.
At HAI, scientists report that tangle accumulation in tracts from the locus coeruleus keeps neural systems from communicating with one another when neurons die.
At Human Amyloid Imaging Conference, Plasma Tau Was the Star When Tau Wanders Off, Subcortical Axon Firing Goes Mum Studying Diverse Populations May Require New Biomarkers After 14 years in Miami, HAI is on the move again. This January conference started
In Puerto Rico, scientists agreed that jointly measuring multiple plasma tau markers could be a powerful readout of tau pathology in a person’s brain.
Scientists characterize early stage tau aggregates and develop a CSF test to track them.
In mice, this marker correlated better with amyloid protofibrils in the brain than with plaques. So did CSF markers of neurodegeneration, highlighting the toxicity of protofibrils.
Two studies tie repeated stretches of DNA to increased odds for AD. One encodes poly-GR peptides that aggregate.
Surveys of CSF proteins from the GENFI and ALLFTD genetic cohorts flag altered biological processes and point toward FTD fluid markers.
An endoplasmic reticulum protein helps lipids bud from this organelle. Knocking out the protein in microglia curtailed lipid droplets, and enhanced amyloid clearance.
A new super-resolution microscopy technique sheds light on synaptic dysfunction.
Mice have a small pool of such Tregs. Removing them hobbles the hippocampus, beckons immune invasion, revs glia, and quashes neurogenesis.
In AD mouse models, replacing ApoE3 with ApoE3Ch preserves memory.
The nod will allow people who have completed 18 months of biweekly IV dosing to transition to monthly IVs. An application for subcutaneous dosing is pending.
No filters selected